Table 2. Results of association analysis for HLA types and CM-SJS/TEN with SOC in Group 1 (KPUM).
| HLA genotype | Carrier frequency (%) | Dominant model analysis | |||
|---|---|---|---|---|---|
| Case (n = 131) | Control (n = 419) | P | Pc | Odds ratio (95% CI) | |
| HLA-A | |||||
| A*02:06 | 62/131 (47.3%) | 57/419 (13.60%) | 2.79.E-16 | 4.75E-15 | 5.71 (3.666-8.881) |
| A*03:01 | 5/131 (3.82%) | 4/419 (0.95%) | 0.0242 | 0.412 | 4.12 (1.089-15.564) |
| A*11:01 | 10/131 (7.6%) | 71/419 (16.95%) | 8.67.E-03 | 0.147 | 0.405 (0.202-0.811) |
| A*24:02 | 57/131 (43.5%) | 256/419 (61.10%) | 3.89.E-04 | 6.60.E-03 | 0.490 (0.330-0.730) |
| HLA-B | |||||
| B*13:01 | 10/131 (7.6%) | 13/419 (3.10%) | 0.0237 | 0.807 | 2.58 (1.104-6.032) |
| B*15:01 | 11/131 (8.4%) | 69/419 (16.47%) | 0.0222 | 0.755 | 0.465 (0.238-0.908) |
| B*44:02 | 5/131 (3.82%) | 5/419 (1.19%) | 0.0498 | 1.69 | 3.29 (0.936-11.532) |
| B*44:03 | 31/131 (23.7%) | 66/419 (15.75%) | 0.0381 | 1.29 | 1.66 (1.024-2.682) |
| B*46:01 | 22/131 (16.8%) | 38/419 (9.07%) | 0.0133 | 0.453 | 2.02 (1.148-3.566) |
| B*52:01 | 12/131 (9.2%) | 79/419 (18.85%) | 9.16.E-03 | 0.311 | 0.434 (0.228-0.825) |
| B*54:01 | 10/131 (7.6%) | 61/419 (14.56%) | 0.0391 | 1.33 | 0.485 (0.241-0.976) |
| HLA-C | |||||
| C*03:04 | 42/131 (32.1%) | 98/419 (23.39%) | 0.0467 | 0.841 | 1.55 (1.00-2.38) |
| C*05:01 | 5/131 (3.82%) | 5/419 (1.19%) | 0.0498 | 0.897 | 3.29 (0.936-11.532) |
| C*12:02 | 13/131 (9.9%) | 80/419 (19.09%) | 0.0145 | 0.262 | 0.467 (0.251-0.870) |
P: P values obtained with χ2-tests.
Pc: P values corrected for the multiplicity of testing by the number of comparisons (17, 34, and 18 for HLA-A, HLA-B and HLA-C, respectively).
CM-SJS/TEN: cold medicine related SJS/TEN who had taken cold medicine.
SOC: severe ocular surface complications.
CI: confidence interval.